Invention Grant
- Patent Title: Methods of treatment using IL-23p19 monoclonal antibodies
-
Application No.: US16435960Application Date: 2019-06-10
-
Publication No.: US11254740B2Publication Date: 2022-02-22
- Inventor: Brenda L. Stevens , Mark W. Rixon , Scott R. Presnell
- Applicant: Bristol-Myers Squibb Company
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Brian J. Walsh
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/24 ; C07K16/46 ; A61K39/00
Abstract:
The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Public/Granted literature
- US20200040072A1 METHODS OF TREATMENT USING IL-23p19 MONOCLONAL ANTIBODIES Public/Granted day:2020-02-06
Information query
